| Study Title | Key Findings | Route | Dose | Year |
|---|---|---|---|---|
| Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial | In subjects with Parkinson's disease, there was no benefit to high cannabidiol (CBD)/low Δ-9-tetrahydrocannabinol (THC) versus placebo. Additionally, there was perhaps worsened cognition and sleep, and many mild adverse events. | Oral (Ingestion) | CLINICAL TRIAL Study Dosing Objective: Effective Dose, Safety Profile Established Protocol: No effective dose Cannabinoid Ratio: (CBD : THC) 191 : 6 Dosage Form: cannabis extract (National Institute of Drug Abuse) oral sesame oil solution (100 mg/mL CBD and 3.3 mg/mL THC) Dosing Regimen: 1.25 mg/kg/day each morning (~1 mL) for 4 ± 1 days and then twice daily for 14 ± 4 days Mean final dose (CBD/THC group) was 191.8 ± 48.9 mg CBD and 6.4 ± 1.6 mg THC daily Maximum Dose: 2.5 mg/kg/day Treatment Duration: 2 weeks Clinical Relevance: CBD/THC did not improve symptoms of Parkinson's disease and may have worsened some, especially cognition. Adverse Events: More common in the CBD-THC group: dizziness, cognitive adverse effects, pneumonia |
2024 |
| Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial | There was no solid evidence in this study that oral cannabidiol therapy reduces the presence of seborrheic dermatitis among this sample of patients with Parkinson's disease. | Oral (Ingestion) | CLINICAL TRIAL Study Dosing Objective: Effective Dose, Safety Profile, Established Protocol: No effective dose Cannabinoid Ratio: (CBD : THC) 100 : 3 Dosage Form: 2.5 mg per kg per day oral sesame solution CBD-rich cannabis extract (formulated to 100 mg/mL CBD and 3.3 mg/mL THC) Dosing Regimen: 1.25 mg per kg per day each morning for 4 ±1 days and then twice daily for 10 ±4 days Treatment Duration: 16 days Clinical Relevance: There was no solid evidence in this study that oral cannabidiol therapy reduces the presence of seborrheic dermatitis among this sample of patients with Parkinson's disease. Adverse Events: no notable changes in blood laboratory studies, including liver tests no unexpected and serious adverse effects no significant dermatological adverse events |
2024 |
| A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease | In subjects with Parkinson's Disease, mixed formulations of THC/CBD were tolerated with no serious adverse effects, and should be considered for further trials as an adjuvant treatment option. | Oral (Ingestion) | CLINICAL TRIAL Study Dosing Objective: Effective Dose, Safety Profile, Established Protocol: Maximum tolerated dose Cannabinoid Ratio: (THC : CBD) 18 : 20 Dosing Regimen: THC/CBD (18:0, 10:10, and 1:20) Clinical Relevance: In subjects with Parkinson's Disease, mixed formulations of THC/CBD were tolerated with no serious adverse effects and should be considered for further trials as an adjuvant treatment option. Adverse Events: no serious AE, most common AE were drowsiness and dizziness (three participants) sleepiness scale scores were higher in the high CBD formulation Additional Notes: Clinical Trial Phase I, Parallel Dose Comparison |
2023 |
| Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms | Subjects given high-dose oral cannabidiol and low-dose oral Δ9-tetrahydrocannabinol performed worse than the placebo group on Animal Verbal Fluency and reported adverse cognitive events at least twice as often as the placebo group. | Oral (Ingestion) | CLINICAL TRIAL Study Dosing Objective: Effective Dose, Established Protocol: No effective dose Cannabinoid Ratio: (CBD : THC) 100 : 3 Dosage Form: a frozen extract CBD 100 mg/mL and THC 3.3 mg/mL sesame oil solution Dosing Regimen: high-dose cannabidiol 100 mg low-dose Δ9-tetrahydrocannabinol 3.3 mg Starting Dose: started at 1.25 mg/kg/day daily for 4 ± 1 days Titration: increased to 1.25 mg/kg/day twice daily (minimum 6 hours apart) for 14 ± 4 days, and adjusted as needed for tolerability Adverse Events: Mild adverse cognitive events |
2023 |
| The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial | This post hoc exploratory analysis of a previously concluded phase II/III double-blind, placebo-controlled clinical trial of patients with both Parkinson's disease (PD) and REM (Rapid Eye Movement) sleep behavior disorder (RBD) who took cannabidiol (CBD) for Restless Legs Syndrome (RLS). Results show CBD did not improve RLS severity in this population. | Oral (Ingestion) | CBD (75-300 mg) |
2022 |
| Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone | Nabilone, a synthetic tetrahydrocannabinol (THC) drug, was effective in improving non-motor symptoms, mood, and sleep in patients with Parkinson's disease. Treatment was overall safe and well tolerated, despite reports of adverse effects in 75% of subjects, though most were mild. | Oral (Ingestion) | Nabilone (0.25 mg - 2 mg per day) |
2020 |
| Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease | Acute CBD administration at a dose of 300 mg decreased anxiety in patients with PD, and there was also decreased tremor amplitude in an anxiogenic situation. | CBD (300 mg) |
2020 | |
| Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease | This study concludes that palmitoylethanolamide (PEA) reduced motor and non-motor symptoms as well as slowed the rate of decline and disability in patients with Parkinson's disease (PD) and supports further research on PEA as an add-on option for patients. | Oral (Ingestion) | Ultra-micronized Palmitoylethanolamide (600 mg) |
2017 |
| Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. | Findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn. | Three study groups: CBD (75 mg/day), CBD (300 mg/day), or placebo |
2014 |
